New targets in pediatric acute myeloid leukemia

Immunology Letters

Volumn 155, Issue 1-2, 2013, Pages 47-50

  Miano, M ^a   Micalizzi, C ^a   Calvillo, M ^a   Dufour, C ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

Acute Myelod Leukemia; Children; Therapeutic advances

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; ALFA 07011; ALISERTIB; ANTHRACYCLINE; ANTIMITOTIC AGENT; ASPARAGINASE MACROGOL; AURORA KINASE INHIBITOR; BARASERTIB; BORTEZOMIB; CD135 ANTIGEN; CLOFARABINE; CPKC 412 A2114; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; GEMTUZUMAB OZOGAMICIN; LESTAURTINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MIDOSTAURIN; POLO LIKE KINASE; PROTEASOME INHIBITOR; PROTEIN KINASE INHIBITOR; QUIZARTINIB; RAPAMYCIN; SORAFENIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VOLASERTIB;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER PROGNOSIS; CHILDHOOD LEUKEMIA; DRUG MEGADOSE; DRUG TARGETING; HUMAN; LOW DRUG DOSE; MONOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SKIN TOXICITY; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION;

ACUTE MYELOD LEUKEMIA; CHILDREN; THERAPEUTIC ADVANCES;

AURORA KINASE A; CHILD; CLINICAL TRIALS AS TOPIC; FMS-LIKE TYROSINE KINASE 3; HUMANS; INDIVIDUALIZED MEDICINE; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; PROTEASOME ENDOPEPTIDASE COMPLEX; TOR SERINE-THREONINE KINASES;

EID: 84887824149     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.09.012     Document Type: Review

References (44)

1. Burnett A., Wetzler M., Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011, 29:487-494.
2. Gibson B.E., Webb D.K., Howman A.J., De Graaf S.S., Harrison C.J., Wheatley K. Results of a randomized trial in children with acute myeloid leukaemia: Medical Research Council AML12 trial. Br J Haematol 2011, 155:366-376.
3. Pui C.H., Carroll W.L., Meshinchi S., Arceci R.J. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011, 29:551-565.
4. Creutzig U., van den Heuvel-Eibrink M.M., Gibson B., Dworzak M.N., Adachi S., de Bont E., et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel, on behalf of the AML Committee of the International BFM Study Group. Blood 2012, 120:3187-3205.
5. Rubnitz J.E., Gibson B., Smith F.O. Acute myeloid leukemia. Pediatr Clin North Am 2008, 55:21-51.
6. Rosnet O., Buhring H.J., Marchetto S., Rappold I., Lavagna C., Sainty D., et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996, 10(2):238-248.
7. Gabbianelli M., Pelosi E., Montesoro E., Valtieri M., Luchetti L., Samoggia P., et al. Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 1995, 86(5):1661-1670. [PubMed: 7544638].
8. Dosil M., Wang S., Lemischka I.R. Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol 1993, 13(10):6572-6585. [PubMed: 7692230].
9. Zhang S., Mantel C., Broxmeyer H.E. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J Leukoc Biol 1999, 65(3):372-380. [PubMed: 10080542].
10. Zhang S., Broxmeyer H.E. Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase. Biochem Biophys Res Commun 2000, 277(1):195-199. [PubMed: 11027663].
11. Marchetto S., Fournier E., Beslu N., Aurran-Schleinitz T., Dubreuil P., Borg J.P., et al. SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia 1999, 13(9):1374-1382. [PubMed: 10482988].
12. Rottapel R., Turck C.W., Casteran N., Liu X., Birnbaum D., Pawson T., et al. Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase. Oncogene 1994, 9(6):1755-1765. [PubMed: 8183574].
13. Lavagna-Sevenier C., Marchetto S., Birnbaum D., Rosnet O. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia 1998, 12(3):301-310. [PubMed: 9529123].
14. Knapper S. The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opin Investig Drugs 2011, 20:1377-1395.
15. Meshinchi S., Alonzo T.A., Stirewalt D.L., Zwaan M., Zimmerman M., Reinhardt D., et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006, 108:3654-3661.
16. Levis M., Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003, 17:1738-1752.
17. Fisher T., et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J. Clin. Oncol. 2010, 28(October (28)):4339-4345.
18. Ravandi F., Cortes J.E., Jones D., Faderl S., Garcia-Manero G., Konopleva M.Y., et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010, 28:1856-1862.
19. Inaba H., Rubnitz J.E., Coustan-Smith E., Li L., Furmanski B.D., Mascara G.P., et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatricrelapsed/refractory leukemia. J Clin Oncol 2011, 29:3293-3300.
20. Carmena M., Earnshaw W.C. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003, 4:842-854.
21. Goldberg S.L., Fenaux P., Craig M.D., Gyan E., Lister J., Kassis J., et al. Phase 2 Study of MLN8237, an investigational aurora A kinase (AAK) inhibitor in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). Blood (ASH Annu Meet Abstr) 2010, 116:3273.
22. Maris J.M., Morton C.L., Gorlick R., Kolb E.A., Lock R., Carol H., et al. Initial testing of theaurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010, 55:26-34.
23. Wen Q., Goldenson B., Silver S.J., Schenone M., Dancik V., Huang Z., et al. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell 2012, 150:575-589.
24. Hartsink-Segers S.A., Zwaan C.M., Exalto C., Luijendijk M.W., Calvert V.S., Petricoin E.F., et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia 2012, 27:560-568.
25. Schöfski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009, 14(June (6)):559-570.
26. Pollard J.A., Alonzo T.A., Loken M., Gerbing R.B., Ho P.A., Bernstein I.D., et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood 2012, 119(April (16)):3705-3711. [Epub 29.02.12]. 10.1182/blood-2011-12-398370.
27. Rubnitz J.E., Inaba H., Dahl G., Ribeiro R.C., Bowman W.P., Taub J., et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010, 11(June (6)):543-552. [Epub 05.05.10]. 10.1016/S1470-2045(10)70090-5.
28. Zwaan C.M., Reinhardt D., Corbacioglu S., van Wering E.R., Bokkerink J.P., Tissing W.J., et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood 2003, 101:3868-3871.
29. Cooper T.M., Franklin J., Gerbing R.B., Alonzo T.A., Hurwitz C., Raimondi S.C., et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the children's oncology group. Cancer 2011, 118:761-769.
30. Satwani P., Bhatia M., Garvin J.H., George D., Dela Cruz F., Le Gall J., et al. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen. Biol Blood Marrow Transplant 2011, 18:324-329.
31. Zwaan C.M., Reinhardt D., Zimmerman M., Hasle H., Stary J., Stark B., et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol 2010, 148:768-776.
32. Aplenc R., Alonzo T.A., Gerbing R.B., Lange B.J., Hurwitz C.A., Wells R.J., et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol 2008, 26:2390-3295.
33. Cooper T.M., Franklin J., Gerbing R.B., Alonzo T.A., Hurwitz C., Raimondi S.C., et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer 2012, 118:761-769.
34. Burnett A.K., Hills R.K., Milligan D., Kjeldsen L., Kell J., Russell N.H., et al. Identificationof patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011, 29:369-377.
35. Hasle H., Abrahamsson J., Forestier E., Ha S.Y., Heldrup J., Jahnukainen K., et al. Gemtuzumab ozogamicin as postconsolidation therapy does not preventrelapse in children with AML: results from NOPHO-AML 2004. Blood 2012, 120:978-984.
36. Castaigne S., Pautas C., Terré C., Raffoux E., Bordessoule D., Bastie J.N., et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012, 379(April (9825)):1508-1516. Acute Leukemia French Association, [Epub 05.04.12]. 10.1016/S0140-6736(12)60485-1.
37. Ravandi F., Estey E.H., Appelbaum F.R., Lo-Coco F., Schiffer C.A., Larson R.A., et al. Gemtuzumab ozogamicin: time to resurrect?. J Clin Oncol 2012, 30(November (32)):3921-3923. [Epub 17.09.12]. 10.1200/JCO.2012.43.0132.
38. Guzman M.L., Swiderski C.F., Howard D.S., Grimes B.A., Rossi R.M., Szilvassy S.J., et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002, 99:16220-16225.
39. Horton T.M., Pati D., Plon S.E., Thompson P.A., Bomgaars L.R., Adamson P.C., et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res 2007, 13(March (5)):1516-1522.
40. Attar E.C., De Angelo D.J., Supko J.G., D'Amato F., Zahrieh D., Sirulnik A., et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008, 14(March (5)):1446-1454. 10.1158/1078-0432.CCR-07-4626.
41. Messinger Y., Gaynon P., Raetz E., Hutchinson R., Dubois S., Glade-Bender J., et al. Phase I study of bortezomib combined with chemotherapy in children withrelapsed childhood acute lymphoblastic leukemia (ALL): a report from thetherapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer 2010, 55:254-259.
42. Martelli A.M., Evangelisti C., Chiarini F., McCubrey J.A. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 2010, 1(June (2)):89-103.
43. Yee K.W., Zeng Z., Konopleva M., Verstovsek S., Ravandi F., Ferrajoli A., et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006, 12(September (17)):5165-5173.
44. Yoshida H., Imamura T., Fujiki A., Hirashima Y., Miyachi M., Inukai T., et al. Post-transcriptional modulation of C/EBPα prompts monocytic differentiation and apoptosis in acute myelomonocytic leukaemia cells. Leuk Res 2012, 36(June (6)):735-741. [Epub 19.09.12]. 10.1016/j.leukres.2012.01.009.